As per the letter attached
LYKALABS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Lyka Labs reported its Q4 and FY26 audited financial results. The company recorded an impairment loss of Rs. 2301.44 Lakhs on its investment and loans in subsidiary Lyka BDR International Limited due to continuous operational losses and eroding net worth. Standalone revenue from operations for FY26 was Rs. 13,469.74 Lakhs, down from Rs. 13,735.74 Lakhs in FY25. The company reported a net loss of Rs. 14.40 Lakhs on standalone basis. The Board also announced a Record Date of June 4, 2026 for the Scheme of Amalgamation where Lyka Exports Limited (Transferor) will merge into Lyka Labs (Transferee). Under this NCLT-approved scheme, shareholders of Lyka Exports will receive 23 equity shares of Lyka Labs for every 100 shares held. The 47th AGM is scheduled for August 10, 2026.
The impairment charge reflects losses in the subsidiary and will impact FY26 earnings, though the clean audit opinion provides some comfort. The upcoming merger with Lyka Exports (NCLT approved March 2026) will dilute existing shareholders by approximately 4.63 lakh new shares and may create near-term stock volatility around the record date.